Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up

• Published in: The Laryngoscope Vol. 132; no. 10; p. 2071
• Main Authors: Ruiz, Ryan, Balamuth, Naomi, Javia, Luv R, Zur, Karen B
• Format: Journal Article
• Language: English
• Published: United States 01.10.2022
• Subjects: Angiogenesis Inhibitors - therapeutic use; Bevacizumab - therapeutic use; Child; Follow-Up Studies; Humans; Neoplasm Recurrence, Local - drug therapy; Papillomavirus Infections - drug therapy; Respiratory Tract Infections - drug therapy; Retrospective Studies; bevacizumab; Recurrent respiratory papillomatosis; papilloma; Avastin
• ISSN: 1531-4995
• DOI: 10.1002/lary.30021

Systemic bevacizumab is a new adjuvant therapy for recurrent respiratory papillomatosis (RRP) that has shown promising preliminary results in children. The objective of this study was to report the largest series to date that includes long-term follow-up data on bevacizumab treatment. Retrospective chart review. Retrospective review of seven pediatric patients treated within the past 6 years with systemic bevacizumab for RRP refractory to traditional debridement. All seven patients had a significant reduction in disease burden after initiation of systemic bevacizumab. There have been no major complications associated with systemic therapy so far. Median duration of bevacizumab treatment was 2.13 years. Three of the seven patients have been on treatment for over 3 years with the longest duration of treatment in our first patient now at 5.5 years. One patient experienced significant disease recurrence on two occasions when therapy was temporarily discontinued and was recently diagnosed with squamous cell carcinoma of the lung. Systemic bevacizumab is an effective therapy for cases of severe RRP with promising results both in short-term and long-term follow-up. Side effects are minimal. Patients must be followed closely to determine appropriate dosing intervals to control disease and to screen for disease progression. 4 Laryngoscope, 132:2071-2075, 2022.